Blueprint Medicines To Present At The 33rd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 8, 2015 /PRNewswire/ -- Blueprint Medicines, a leader in discovering and developing kinase drugs to treat patients with genetically defined diseases, today announced that Jeffrey Albers, Chief Executive Officer, will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 9:30 a.m. PST at the Westin St. Francis Hotel in San Francisco, CA.
About Blueprint Medicines
Blueprint Medicines makes kinase drugs to treat patients with genetically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer. Blueprint Medicines is privately held and raised $115 million in financing since its 2011 inception. For more information, please visit www.BlueprintMedicines.com.
Contact:
Investor Relations:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
beth@sternir.com
Media Relations:
David Polk
Chandler Chicco Companies
310-309-1029
dpolk@chandlerchiccocompanies.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-the-33rd-annual-jp-morgan-healthcare-conference-300017569.html
SOURCE Blueprint Medicines